Reanalysis of JUPITER clinical trial (NCT00239681)- Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Table: Reanalysis of adverse events<br>NCT00239681: JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events Chi-square statistics ______ 1. Not all adverse drug reactions are included in this Table. 2. Adverse events appear to be much higher than 18%. (1) 3. Results available at ClinicalTrials.gov for the JUPITER study are not consistent with publications reporting the results of this trial. http://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00239681 For example: - Discordance between results reported in the number of patients diagnosed with diabetes mellitus. 1. ClinicalTrials.gov: Placebo=13; Rosuvastatin=14 | 2. Article (PMID: 22883507): Placebo=216; Rosuvastatin=270) 4. Primary outcome was modified in the registry history available at ClinicalTrials.gov http://clinicaltrials.gov/archive/NCT00239681/2014_03_21/changes 5. It is not clear why the study was terminated. <strong>March 13, 2008.</strong> <br><em>"Independent Data Monitoring Committee for JUPITER met and agreed that the studyshould continue as planned."</em> <strong>April 2, 2008.</strong><em> <br>"AstraZeneca announced it has decided to stop the CRESTOR JUPITER clinicalstudy early based on a recommendation from an Independent Data Monitoring Boardand the JUPITER Steering Committee, which met on March 29, 2008. The study willbe stopped early because there is unequivocal evidence of a reduction incardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo."</em> http://clinicaltrials.gov/archive/NCT00239681/2008_04_02/changes <strong>References</strong> 1. Should people at low risk of cardiovascular disease take a statin? BMJ 2014; 348:g3329